Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 8;18(8):e0289642.
doi: 10.1371/journal.pone.0289642. eCollection 2023.

Cognition and education benefits of increased hemoglobin and blood oxygenation in children with sickle cell disease

Joanna P MacEwan  1 , Allison A King  2 , Andy Nguyen  3 , Anuj Mubayi  1 , Irene Agodoa  3 , Kim Smith-Whitley  3   4
Affiliations

Cognition and education benefits of increased hemoglobin and blood oxygenation in children with sickle cell disease

Joanna P MacEwan et al. PLoS One. .

Abstract

Background: Among individuals with sickle cell disease (SCD), decreased hemoglobin is associated with lower oxygen saturation (SpO2) and increased risk of stroke, both of which are associated with lower intelligence quotient (IQ) scores. Thus, increasing hemoglobin and SpO2 in individuals with SCD may increase IQ and educational attainment.

Methods: A cohort simulation model was built to determine academic performance and educational attainment based on cognitive function (measured by IQ) of a pediatric SCD cohort randomly assigned to treatment and control groups. The model contained two key stages: childhood (<10 years) and adolescence (≥10 years). In stage 1, increased hemoglobin and increased SpO2 (assigned to the treatment group) were determinants of higher IQ, prevention of IQ deterioration over time. Increased hemoglobin was also a determinant of decreased stroke risk. In stage 2, improvement in adolescent IQ as a result of treatment was a determinant of academic performance.

Results: In a simulated cohort of 2000 children and adolescents with SCD (52.5% female, 50% treated), stroke incidence was predicted to be 44.4% lower among the treated group than the untreated group (4.5% versus 8.1%, respectively). The average IQ among the treated group was estimated to be 91.1 compared with 82.9 in the untreated group (a 9.9% difference; P<0.001). Finally, high school (≥12 years of education) completion rates were estimated to be 64.7% higher among the treated group: 76.1% of the treated group was projected to complete high school compared with 46.2% of the untreated group.

Conclusions: Our model predicts that an average improvement in hemoglobin of 1.1 g/dL (11 g/L) among individuals with SCD may be associated with improved neurocognition and educational outcomes. These improvements may also generate benefits not captured by our model, including improved quality of life, employment, and income.

PubMed Disclaimer

Conflict of interest statement

Joanna P. MacEwan: Current employee of Genesis Research, former employee of PRECISIONheor, a life sciences research consulting firm paid by Global Blood Therapeutics, Inc., to conduct this study; research funding from NHLBI, HRSA, PCORI, and ASH. Allison A. King: Research funding from Global Blood Therapeutics, Inc. Kim Smith-Whitley: Former employee of Global Blood Therapeutics, Inc., at the time of the study; Andy Nguyen and Irene Agodoa: Former employees at Global Blood Therapeutics, Inc., at the time of the study. Anuj Mubayi: Current employee of The Public Health Company, former employee of PRECISIONheor, a life sciences research consulting firm paid by Global Blood Therapeutics, Inc, to conduct this study. Global Blood Therapeutics, Inc. is a wholly owned subsidiary of Pfizer Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Model diagram.
Hb, hemoglobin; IQ, intelligence quotient; SCD, sickle cell disease.
Fig 2
Fig 2. Distribution of IQ score (A) and years of education completed (B) by treatment status (A, B) and sex (B).
IQ, intelligence quotient.
See this image and copyright information in PMC

References

    1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(suppl 4):S512–21. Epub 2010/04/02. doi: 10.1016/j.amepre.2009.12.022 . - DOI - PubMed
    1. Farber MD, Koshy M, Kinney TR. Cooperative Study of Sickle Cell Disease: demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis. 1985;38(6):495–505. Epub 1985/01/01. doi: 10.1016/0021-9681(85)90033-5 . - DOI - PubMed
    1. Lubeck D, Agodoa I, Bhakta N, Danese M, Pappu K, Howard R, et al.. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11):e1915374–e. doi: 10.1001/jamanetworkopen.2019.15374 - DOI - PMC - PubMed
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al.. Mortality in sickle cell disease–life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–44. Epub 1994/06/09. doi: 10.1056/NEJM199406093302303 . - DOI - PubMed
    1. Manci EA, Culberson DE, Yang Y-M, Gardner TM, Powell R, Haynes J Jr., et al.. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123:359–65. doi: 10.1046/j.1365-2141.2003.04594.x - DOI - PubMed

Publication types